ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1221

Evaluation of Methotrexate Efficacy and Exploration of Metabolites Associated with Disease Activity in Collagen-induced Arthritis Mouse Model
Abstract Number: 1996

Evaluation of Response to Pneumococcal Vaccination in Patients with Rheumatoid Arthritis Receiving Upadacitinib: Results from a Phase 2 Open-Label Extension Study
Abstract Number: 0377

Evaluation of Sex Differences in the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
Abstract Number: 0599

Evaluation of Telephone Consultations in Germany as an Additional Tool in Outpatient Rheumatology Clinics During the COVID-19 Pandemic
Abstract Number: 0265

Evaluation of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus as a Measure of Systemic Lupus Erythematosus (SLE) Disease Activity from the Clinician and the Patient Perspective: Experience from an Italian Cohort
Abstract Number: 0542

Examining the Long-Term and Short-Term Day-To-Day Pain Variability in Inflammatory and Non-Inflammatory Rheumatic and Musculoskeletal Diseases Using Multilevel and Markov Transition Models: Cloudy with a Chance of Pain, a National U.K. Smartphone Study
Abstract Number: 0543

Exercise Among Older Adults Living with Rheumatic Disease: Physical Activity Habits and Patient Reported Outcomes
Abstract Number: 1883

Exercise Partially Explains the Impact of Body Mass Index on Disease Activity in Ankylosing Spondylitis
Abstract Number: 0292

Exhausted pSTAT5-IFNα Signaling Pathways in SLE Patients Are Correlated with Age-associated B Cells and Disease Activity
Abstract Number: 0977

Expanded T Peripheral Helper Cells and Increased Pathologic B Cell Lung Infiltration in Pristane-induced Murine Lupus in the Absence of BCL6+ Tfh Cells
Abstract Number: 1783

Experience of Pregnant Rheumatology Outpatients from a Tertiary Hospital in New York City During the COVID-19 Pandemic
Abstract Number: 0365

Experience with Apremilast in Treatment of Psoriatic Arthritis in US Clinical Practice; Assessments from Trio Health and the American Rheumatology Network (ARN)
Abstract Number: 0012

Experiences of Patients with Rheumatic Diseases in the US During the Early Months of the COVID-19 Pandemic
Abstract Number: 1302

Exploration of Machine Learning Methods in Predicting Systemic Lupus Erythematosus Hospitalizations
Abstract Number: 0410

Exploring Gene Expression Profile of Primary Central Nervous System Vasculitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].